Clarus Therapeutics Holdings Total Revenue

Clarus Therapeutics Holdings (CRXT) currently reports a total revenue of $19M as of June 2022. That compares with $5M in the prior-year period — up 284.5% year over year. That is below the sector sector average of $1.3B. Use the charts on this page to explore Clarus Therapeutics Holdings's total revenue history and peer comparisons.

Clarus Therapeutics Holdings's total revenue increased from $5M to $19M — a 284.5% year-over-year increase (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clarus Therapeutics Holdings's total revenue of $19M is lower than the its sector sector average of $1.3B. That is roughly 98.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Clarus Therapeutics Holdings reported $19M in total revenue as of June 2022. That compares with $5M in the prior-year period — up 284.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $1.3B. From there, open related valuation or income-statement pages for Clarus Therapeutics Holdings, and consider following CRXT for alerts when major investors trade the stock.